11.00
price down icon2.14%   -0.24
after-market After Hours: 11.07 0.07 +0.64%
loading
Viatris Inc stock is currently priced at $11.00, with a 24-hour trading volume of 5.35M. It has seen a -2.14% decreased in the last 24 hours and a +8.16% rose in the past month. The chart indicates a potential bearish trend, as the stock is below the $11.29 pivot point. If it approaches the $10.93 support level, significant changes may occur.
Previous Close:
$11.24
Open:
$11.23
24h Volume:
5.35M
Market Cap:
$13.10B
Revenue:
$15.36B
Net Income/Loss:
$-56.10M
P/E Ratio:
7.1895
EPS:
1.53
Net Cash Flow:
$2.00B
1W Performance:
+3.68%
1M Performance:
+8.16%
6M Performance:
-5.82%
1Y Performance:
+8.27%
1D Range:
Value
$10.96
$11.23
52W Range:
Value
$8.74
$13.62

Viatris Inc Stock (VTRS) Company Profile

Name
Name
Viatris Inc
Name
Phone
(724) 514-1465
Name
Address
1000 MYLAN BOULEVARD, CANONSBURG
Name
Employee
38,000
Name
Twitter
Name
Next Earnings Date
2024-08-05
Name
Latest SEC Filings
Name
VTRS's Discussions on Twitter

Viatris Inc Stock (VTRS) Upgrades & Downgrades

Date Action Analyst Rating Change
Oct-23-23 Downgrade BofA Securities Neutral → Underperform
Jun-23-23 Downgrade Barclays Equal Weight → Underweight
Apr-24-23 Downgrade Barclays Overweight → Equal Weight
Feb-17-23 Downgrade BMO Capital Markets Outperform → Market Perform
Jan-27-23 Upgrade Jefferies Hold → Buy
Nov-10-22 Upgrade UBS Sell → Neutral
Nov-08-22 Upgrade Piper Sandler Underweight → Neutral
Oct-21-22 Resumed Jefferies Hold
Jun-14-22 Initiated UBS Sell
May-10-22 Downgrade Piper Sandler Neutral → Underweight
Mar-01-22 Downgrade BofA Securities Buy → Neutral
Mar-01-22 Downgrade Raymond James Outperform → Mkt Perform
Jun-15-21 Initiated Citigroup Neutral
Apr-07-21 Resumed RBC Capital Mkts Outperform
Mar-08-21 Downgrade Goldman Buy → Neutral
Mar-02-21 Downgrade JP Morgan Overweight → Neutral
Feb-26-21 Downgrade Wolfe Research Outperform → Peer Perform
Jan-05-21 Initiated Argus Hold
Dec-14-20 Initiated Bernstein Mkt Perform
View All

Viatris Inc Stock (VTRS) Financials Data

Viatris Inc (VTRS) Revenue 2024

VTRS reported a revenue (TTM) of $15.36 billion for the quarter ending March 31, 2024, a -2.78% decline year-over-year.
loading

Viatris Inc (VTRS) Net Income 2024

VTRS net income (TTM) was -$56.10 million for the quarter ending March 31, 2024, a -102.95% decrease year-over-year.
loading

Viatris Inc (VTRS) Cash Flow 2024

VTRS recorded a free cash flow (TTM) of $2.00 billion for the quarter ending March 31, 2024, a -14.22% decrease year-over-year.
loading

Viatris Inc (VTRS) Earnings per Share 2024

VTRS earnings per share (TTM) was -$0.06 for the quarter ending March 31, 2024, a -103.82% decline year-over-year.
loading
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
drug_manufacturers_specialty_generic RDY
$80.44
price up icon 1.07%
$147.46
price up icon 0.02%
$57.84
price up icon 0.45%
$123.19
price down icon 0.19%
$78.69
price up icon 0.72%
Cap:     |  Volume (24h):